Life Science

A post-synaptic &alpha1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia displays high-affinity with non-selectivity for the three known human &alpha1 adrenoceptors

A post-synaptic &alpha1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia displays high-affinity with non-selectivity for the three known human &alpha1 adrenoceptors

A post-synaptic &alpha1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia displays high-affinity with non-selectivity for the three known human &alpha1 adrenoceptors

A nonpeptide renin inhibitor (IC₅₀ = 0.6 nM) that selectively binds to the S3 sub-pocket of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby blocking eventual conversion to angiotensin II reduces blood

A nonpeptide renin inhibitor (IC₅₀ = 0.6 nM) that selectively binds to the S3 sub-pocket of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby blocking eventual conversion to angiotensin II reduces blood

A nonpeptide renin inhibitor (IC₅₀ = 0.6 nM) that selectively binds to the S3 sub-pocket of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby blocking eventual conversion to angiotensin II reduces blood

A nonpeptide renin inhibitor (IC₅₀ = 0.6 nM) that selectively binds to the S3 sub-pocket of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby blocking eventual conversion to angiotensin II reduces blood

AZD-3463 is an inhibitor of anaplastic lymphoma kinase (ALK) and insulin-like growth factor 1 receptor (IGF-1R). This compound exhibits anticancer chemotherapeutic activity, inhibiting proliferation by altering downstream ERK/Akt/STAT3 signaling.

AZD-3463 is an inhibitor of anaplastic lymphoma kinase (ALK) and insulin-like growth factor 1 receptor (IGF-1R). This compound exhibits anticancer chemotherapeutic activity, inhibiting proliferation by altering downstream ERK/Akt/STAT3 signaling.

AZD-3463 is an inhibitor of anaplastic lymphoma kinase (ALK) and insulin-like growth factor 1 receptor (IGF-1R). This compound exhibits anticancer chemotherapeutic activity, inhibiting proliferation by altering downstream ERK/Akt/STAT3 signaling.

ASP-3026 inhibits anaplastic lymphoma kinase (ALK) and shows anticancer chemotherapeutic activity. Treatment with ASP-3026 lowers tumor burden in lung and intrapleural tumor models.

ASP-3026 inhibits anaplastic lymphoma kinase (ALK) and shows anticancer chemotherapeutic activity. Treatment with ASP-3026 lowers tumor burden in lung and intrapleural tumor models.